CONMED Corp(CNMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,708 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CNMD Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for CONMED Corp (CNMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CNMD at 48.7/100 on a 32-signal composite quality model, placing it at rank #1,708 of 2,961 stocks — the bottom half of the AI-ranked universe. CNMD scores in the top quartile across earnings quality (87.7). Areas of concern include institutional flow (23.6) and profitability (35.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 39.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CONMED Corp reports quarterly revenue of $343.5M, net income of $23.1M, an operating margin of 10.6%. Top institutional holders of CNMD by reported 13-F value include BlackRock, EARNEST PARTNERS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. CNMD trades on the NYSE exchange and files with the SEC under CIK 816956. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CONMED Corp directly from SEC EDGAR. CONMED Corp's 13F Pro composite quality score has ranged between 35 and 66 since 2021, currently 48.7 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$343.5M
Net Income
Q2 2026
$23.1M
Operating Margin
Q2 2026
10.6%
ROIC
Q2 2026
7.8%
D/E Ratio
Q2 2026
0.80
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+5.2% YoYNet Income
-64.5% YoYOperating Income
-48.8% YoYEPS (Diluted)
-64.5% YoYTotal Assets
+0.8% YoYTotal Debt
-7.8% YoYOp. Cash Flow
+2.2% YoYFree Cash Flow
-2.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.37B +5.2% | $1.31B +5.0% | $1.24B +19.1% | $1.05B +3.4% | $1.01B +17.2% | $862.5M |
| Net Income | $47.1M -64.5% | $132.4M +105.4% | $64.5M +180.0% | $-80.6M -228.8% | $62.5M +557.2% | $9.5M |
| Operating Income | $102.6M -48.8% | $200.3M +66.1% | $120.6M +72.2% | $70.1M -36.2% | $109.7M +138.5% | $46.0M |
| EPS (Diluted) | $1.51 -64.5% | $4.25 +108.3% | $2.04 +176.1% | $-2.68 -238.1% | $1.94 +506.2% | $0.32 |
| Total Assets | $2.33B +0.8% | $2.31B +0.3% | $2.30B +0.1% | $2.30B +30.1% | $1.77B +0.8% | $1.75B |
| Total Debt | $834.9M -7.8% | $905.8M -7.0% | $973.8M -7.7% | $1.05B +54.1% | $684.7M -9.2% | $753.6M |
| Operating Cash Flow | $170.7M +2.2% | $167.0M +33.2% | $125.3M +275.7% | $33.4M -70.1% | $111.8M +73.2% | $64.5M |
| Free Cash Flow | $150.9M -2.0% | $153.9M +44.7% | $106.3M +818.1% | $11.6M -88.1% | $96.9M +88.1% | $51.5M |
Get alerted when CNMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CONMED Corp including:
Top Institutional Holders of CNMD
BlackRock, Inc.
$157.8M4,820,739 shEARNEST PARTNERS LLC
$82.0M2,505,295 shVANGUARD PORTFOLIO MANAGEMENT LLC
$71.6M2,188,761 shOAKTREE CAPITAL MANAGEMENT LP
$52.5M53,645,000 shFULLER & THALER ASSET MANAGEMENT, INC.
$51.7M1,579,917 shSTATE STREET CORP
$46.4M1,417,468 shVANGUARD CAPITAL MANAGEMENT LLC
$44.4M1,355,728 shBANK OF AMERICA CORP /DE/
$43.9M1,341,409 shDIMENSIONAL FUND ADVISORS LP
$43.1M1,317,370 shSEI INVESTMENTS CO
$32.3M988,151 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $157.8M | 4,820,739 |
| EARNEST PARTNERS LLC | $82.0M | 2,505,295 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $71.6M | 2,188,761 |
| OAKTREE CAPITAL MANAGEMENT LP | $52.5M | 53,645,000 |
| FULLER & THALER ASSET MANAGEMENT, INC. | $51.7M | 1,579,917 |
| STATE STREET CORP | $46.4M | 1,417,468 |
| VANGUARD CAPITAL MANAGEMENT LLC | $44.4M | 1,355,728 |
| BANK OF AMERICA CORP /DE/ | $43.9M | 1,341,409 |
| DIMENSIONAL FUND ADVISORS LP | $43.1M | 1,317,370 |
| SEI INVESTMENTS CO | $32.3M | 988,151 |
Companies Similar to CNMD
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Pacira BioSciences, Inc.
Enovis CORP
Envista Holdings Corp
HAEMONETICS CORP
INTEGRA LIFESCIENCES HOLDINGS CORP
Amphastar Pharmaceuticals, Inc.
Prestige Consumer Healthcare Inc.
Integer Holdings Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CNMD on your watchlist
Track score changes the day CONMED Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CNMD a good stock to buy?
13F Pro's AI-powered analysis of CONMED Corp (CNMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CNMD are available on the CNMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CNMD is classified as a small company.
Which hedge funds own CNMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CNMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CONMED Corp's investment landscape.